Ascent Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ascent Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$446K	Sell	2,817 -578	-17%	-$78.1K	0.01%	559
2026 Q1	$434K	Sell	3,395 -488	-13%	-$60.9K	0.02%	530
2025 Q4	$473K	Buy	+3,883	New	+$445K	0.02%	507
2024 Q4	–	Sell	-7,935	Closed	-$784K	–	556
2024 Q3	$784K	Buy	+7,935	New	+$780K	0.06%	316
2022 Q2	–	Sell	-23,536	Closed	-$2.12M	–	510
2022 Q1	$2.12M	Buy	+23,536	New	+$2.17M	0.25%	142

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Ascent Group's XBI Position: Q2 2026 in Review

Ascent Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 17% in Q2 2026, selling an estimated $78.1K and leaving 2,817 shares worth $446K. The position accounts for 0.01% of the portfolio, ranked #559.

Ascent Group first reported a position in XBI in Q1 2022 and has held it in 5 quarters since. The position peaked at $2.12M in Q1 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Ascent Group held 2,817 shares of State Street SPDR S&P Biotech ETF worth $446K as of Q2 2026.
Ascent Group sold 578 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $78.1K.
State Street SPDR S&P Biotech ETF made up 0.01% of Ascent Group's portfolio in Q2 2026, its #559 holding.
Ascent Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 5 quarters since.
Ascent Group's State Street SPDR S&P Biotech ETF position peaked at $2.12M in Q1 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.